Clinical response of patients with galactorrhea to pergolide, a potent, long-acting dopaminergic ergot derivative

John Callaghan, R. E. Cleary, R. Crabtree, L. Lemberger

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Pergolide is an ergot derivative with dopaminergic activity and, like bromocriptine, can suppress prolactin release from the pituitary gland. In a single blind study pergolide was administered for 90 days to three females with idiopathic hyperprolactinemia manifested by galactorrhea and amenorrhea. Response to therapy was followed clinically and by determination of plasma prolactin concentrations. Pergolide lowered plasma prolactin concentrations and suppressed galactorrhea in all patients. Menstruation recurred in both patients with intact GU systems. Side effects were minor and tolerance developed to all but nasal stuffiness. Pergolide appears to be efficacious therapy for patients with amenorrhea/galactorrhea secondary to hyperprolactinemia.

Original languageEnglish
Pages (from-to)95-102
Number of pages8
JournalLife Sciences
Volume28
Issue number1
DOIs
StatePublished - Jan 5 1981

Fingerprint

Pergolide
Galactorrhea
Prolactin
Derivatives
Amenorrhea
Single-Blind Method
Plasmas
Hyperprolactinemia
Menstruation
Bromocriptine
Pituitary Gland
Nose
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Clinical response of patients with galactorrhea to pergolide, a potent, long-acting dopaminergic ergot derivative. / Callaghan, John; Cleary, R. E.; Crabtree, R.; Lemberger, L.

In: Life Sciences, Vol. 28, No. 1, 05.01.1981, p. 95-102.

Research output: Contribution to journalArticle

@article{8ce5b8c45afd49c1bcc7057ae3e55d27,
title = "Clinical response of patients with galactorrhea to pergolide, a potent, long-acting dopaminergic ergot derivative",
abstract = "Pergolide is an ergot derivative with dopaminergic activity and, like bromocriptine, can suppress prolactin release from the pituitary gland. In a single blind study pergolide was administered for 90 days to three females with idiopathic hyperprolactinemia manifested by galactorrhea and amenorrhea. Response to therapy was followed clinically and by determination of plasma prolactin concentrations. Pergolide lowered plasma prolactin concentrations and suppressed galactorrhea in all patients. Menstruation recurred in both patients with intact GU systems. Side effects were minor and tolerance developed to all but nasal stuffiness. Pergolide appears to be efficacious therapy for patients with amenorrhea/galactorrhea secondary to hyperprolactinemia.",
author = "John Callaghan and Cleary, {R. E.} and R. Crabtree and L. Lemberger",
year = "1981",
month = "1",
day = "5",
doi = "10.1016/0024-3205(81)90371-4",
language = "English",
volume = "28",
pages = "95--102",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Clinical response of patients with galactorrhea to pergolide, a potent, long-acting dopaminergic ergot derivative

AU - Callaghan, John

AU - Cleary, R. E.

AU - Crabtree, R.

AU - Lemberger, L.

PY - 1981/1/5

Y1 - 1981/1/5

N2 - Pergolide is an ergot derivative with dopaminergic activity and, like bromocriptine, can suppress prolactin release from the pituitary gland. In a single blind study pergolide was administered for 90 days to three females with idiopathic hyperprolactinemia manifested by galactorrhea and amenorrhea. Response to therapy was followed clinically and by determination of plasma prolactin concentrations. Pergolide lowered plasma prolactin concentrations and suppressed galactorrhea in all patients. Menstruation recurred in both patients with intact GU systems. Side effects were minor and tolerance developed to all but nasal stuffiness. Pergolide appears to be efficacious therapy for patients with amenorrhea/galactorrhea secondary to hyperprolactinemia.

AB - Pergolide is an ergot derivative with dopaminergic activity and, like bromocriptine, can suppress prolactin release from the pituitary gland. In a single blind study pergolide was administered for 90 days to three females with idiopathic hyperprolactinemia manifested by galactorrhea and amenorrhea. Response to therapy was followed clinically and by determination of plasma prolactin concentrations. Pergolide lowered plasma prolactin concentrations and suppressed galactorrhea in all patients. Menstruation recurred in both patients with intact GU systems. Side effects were minor and tolerance developed to all but nasal stuffiness. Pergolide appears to be efficacious therapy for patients with amenorrhea/galactorrhea secondary to hyperprolactinemia.

UR - http://www.scopus.com/inward/record.url?scp=0019367154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019367154&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(81)90371-4

DO - 10.1016/0024-3205(81)90371-4

M3 - Article

VL - 28

SP - 95

EP - 102

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 1

ER -